Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes

Ewha Womans University, Sŏul, Seoul, South Korea
Atherosclerosis (Impact Factor: 3.99). 09/2007; 194(1):230-7. DOI: 10.1016/j.atherosclerosis.2006.07.031
Source: PubMed


Tissue factor (TF) plays a pivotal role in thrombus formation. Statins and angiotensin converting enzyme inhibitors attenuate expression of TF by distinct mechanism. Therefore, we hypothesized that combined therapy with simvastatin and ramipril may have additive beneficial anti-atherogenic effects to lower TF activity when compared with either drug alone. This was a randomized, double-blind, placebo-controlled cross-over trial with three treatment arms (each 2 months) and two washout periods (each 2 months). Fifty patients with type 2 diabetes were given simvastatin 20 mg and placebo, simvastatin 20 mg and ramipril 10 mg, or ramipril 10 mg and placebo daily during each treatment period. Simvastatin and ramipril monotherapy tended to reduce TF activity (0.53 to 0.46 nM, P=0.056; 0.54 to 0.50 nM, P=0.167, respectively) while combined therapy had a significant effect (0.64 to 0.43 nM, P<0.001). All three therapies significantly reduced prothrombin fragment 1+2 (F1+2) levels from their respective baselines (P=0.037, P<0.001, and P=0.057, respectively). Combined therapy significantly reduced TF activity and F1+2 levels to a greater extent than either simvastatin or ramipril alone (P=0.029 and P=0.040 by ANOVA, respectively). Percent changes in TF activity and percent changes in F1+2 levels were significantly correlated. All three therapies reduced CD40 ligand levels from their respective baselines (P=0.098, P<0.001, and P=0.002, respectively) with no significant differences among these three therapies (P=0.204 by ANOVA). Ramipril combined with simvastatin significantly reduces plasma TF activity and F1+2 levels to a greater extent than monotherapy with either drug in patients with type 2 diabetes.

15 Reads
    • "Evidence concerning the benefits of other classes of antihypertensive agents is much more limited. Recent studies demonstrated that the angiotensin converting enzyme inhibitor (ACEIs) ramipril either in combination [111] or as a monotherapy [112] is capable of lowering sCD40L levels in various clinical settings. In contrast to ARBs, which directly block the Ang II receptors and therefore have a direct antiplatelet effect, ACEIs have a relatively indirect influence on the effect of Ang II on platelets, in that they prevent its formation . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Soluble CD40 ligand (sCD40L) is involved in the pathogenesis of risk factor-related vascular damage and has been regarded as a molecular link between inflammation, thrombosis and angiogenesis. Given the increasingly recognized theory that hypertension is in part an inflammatory disorder, the contribution of CD40/CD40L dyad is becoming one of the outstanding puzzles in the pathophysiology of hypertension. CD40/CD40L signaling appears, in fact, like a versatile pathway that vehicles information within vascular cells. Several distinct lines of investigation in the context of hypertension dealing with low-grade inflammation are now merging, with CD40/CD40L system as the missing link. As an example, recent data suggest that the vasoactive peptide angiotensin II promotes and augments the inflammatory activation induced by CD40/CD40L ligation in human vascular cells. Accordingly, sCD40L levels are elevated in hypertensive patients and might discriminate hypertensive patients at a high risk of cardiovascular events. This review will summarize the present understanding of the contribution of sCD40L to inflammation, thrombosis and neoangiogenesis in hypertension. Furthermore, given the well established effects that antihypertensive drugs exert on the vasculature beyond blood pressure lowering (pleiotropic effects), we will also discuss the effects of antihypertensive treatment on these phenomena.
    Cardiovascular & Haematological Disorders - Drug Targets(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders) 10/2008; 8(3):194-202. DOI:10.2174/187152908785849125
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 2 diabetes is a chronic metabolic disorder that results from defects in both insulin action and secretion, which is now increasing at pace throughout the world, and its intensity of occurrence can be inferred by the International Diabetes Federation (IDF) 2006 report stating that around 246 million people worldwide are suffering from this disease and the prevalence is expected to cross the figure of 380 million within 20 years.Traditional treatment strategies include various oral hypoglycemic agents but practically none of these agents maintain glucose levels indefinitely and thus many type 2 diabetics require exogenous insulin therapy. Although combination therapies are available, however, these drug combinations have limitations in their application to late stage type 2 diabetics. To overcome these issues new treatment strategies are being developed. This review is an attempt to focus on detailed aspects of several recent approaches based on receptors targeting, acetyl-CoA carboxylase 2, I kappa kinase (IKK) beta (IKKB), islet cell transplantation, gene expression profiling, glucagon-like peptide-1 (GLP-1), dipeptidyl peptidase IV inhibitors, CSII (insulin pump therapy), nuclear receptors as drug targets, modulators of peroxisome proliferator-activated receptors (PPAR), glucagon receptor antagonists, insulin receptor activators and protein tyrosine phosphatase inhibitors, combination therapies together with latest findings aimed at identifying new antidiabetic agents with novel mechanisms. Further exploration of these targets will hopefully lead to safe and efficacious drugs that will become the mainstays of next generation therapeutics for diabetes.
    Diabetes and Metabolic Syndrome Clinical Research and Reviews 01/2010; 4(1-4):48-56. DOI:10.1016/j.dsx.2008.04.011
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Endothelial dysfunction is universal in diabetes, being intimately involved with the development of cardiovascular disease. The pathogenesis of endothelial dysfunction in diabetes is complex. It is initially related to the effects of fatty acids and insulin resistance on 'uncoupling' of both endothelial nitric oxide synthase activity and mitochondrial function. Oxidative stress activates protein kinase C (PKC), polyol, hexosamine and nuclear factor kappa B pathways, thereby aggravating endothelial dysfunction. Improvements in endothelial function in the peripheral circulation in diabetes have been demonstrated with monotherapies, including statins, fibrates, angiotensin-converting enzyme (ACE) inhibitors, metformin and fish oils. These observations are supported by large clinical end point trials. Other studies show benefits with certain antioxidants, L-arginine, folate, PKC-inhibitors, peroxisome proliferator activated receptor (PPAR)-alpha and -gamma agonists and phosphodiesterase (PDE-5) inhibitors. However, the benefits of these agents remain to be shown in clinical end point trials. Combination treatments, for example, statins plus ACE inhibitors and statins plus fibrates, have also been demonstrated to have additive benefits on endothelial function in diabetes, but there are no clinical outcome data to date. Measurement of endothelial dysfunction in cardiovascular research can provide fresh opportunities for exploring the mechanism of benefit of new therapeutic regimens and for planning and designing large clinical trials.
    Diabetes & Vascular Disease Research 07/2007; 4(2):89-102. DOI:10.3132/dvdr.2007.026 · 2.83 Impact Factor
Show more